The market for those next-gen tests is still in its "infancy," she points out. It's true that 23andMe doesn't have too much to worry about in the near future. Rivals who are betting on advanced sequencing, such as Color Genomics, Helix and Veritas Genetics, are only just getting started. Whether or not they succeed is still up in the air, and 23andMe hasn't had trouble finding interest among scientists wanting to use its genetic data for medical research. There's more of a concern for its long-term future: what if that next-gen data becomes extremely useful? BuzzFeed understands that 23andMe let go of key scientists as part of its strategy shift, and it might take a while to get back up to speed if the company needs to step up its sequencing game. Update: In an interview at WSJD Live, Wojcicki gave a more detailed explanation behind the move to discontinue next-gen genetic sequencing. "Next-generation sequencing is the hot shiny object," she said. "But what you're going to do with all that information is extremely complicated." If the results read something like you had a 5 percent chance of getting breast cancer, what would you do then? Need you do anything at all? It's a highly complex question, she said, one that hasn't been made clear just yet. Ultimately, she said that 23andme is a direct-to-consumer product, and that means that the results it provides needs to be extremely clear. Plus there are already more expensive, disease-specific tests that you can take. "We want to give information to individuals where there's no ambiguity," she said.
Co-founder of 23andMe, Anne Wojcicki, said the company has halted research into next-gen sequencing (NGS) of clients' genomic data, choosing to focus on its core business. Although she acknowledged the demand for NGS, she also said, “We want to give information to individuals where there's no ambiguity.” The move comes as a number of companies are trying to make sense out of the explosion in data generated by big data.